SANTA BARBARA, Calif.--(BUSINESS WIRE)--Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetics market, announced today that it has taken the first steps toward entry into the U.S. neurological marketplace by completion of enrollment in the Phase I study in its U.S. investigational study of botulinum toxin type A for torticollis/ cervical dystonia.
